ARQT Live signals | Maximize Profits with Getagraph.com

BUY 12807 min ago

@ $12.30

Issued: 11 Apr 2024 @ 12:30

Return: -26.02%

Previous signal: Apr 11 - 10:25

Previous signal: Sell

Return: -0.89 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	4.52M
Average Volume	4.66M
Market Cap	1.05B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.650 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.41
ATR14	$0.0330 (0.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Topper David Joseph	Buy	310 000	Stock Option (right to buy)
2024-04-10	Topper David Joseph	Buy	110 000	Common Stock
2024-04-10	Topper David Joseph	Sell	7 500	Stock Option (right to buy)
2024-03-04	Matsuda Masaru	Sell	3 760	Common Stock
2024-03-04	Burnett Patrick	Sell	4 782	Common Stock

INSIDER POWER
30.78
Last 98 transactions
Buy: 3 267 821 \| Sell: 1 662 580

Volume Correlation

Long: 0.31 (neutral)

Short: 0.94 (very strong)

Signal:(74.094) Expect same movement, but be aware

Arcutis Biotherapeutics Correlation

10 Most Positive Correlations
RCKY	0.919
MORN	0.915
WBA	0.911
CPTN	0.907
CSSE	0.905
PENN	0.903
CNSL	0.902
ENNV	0.901
CSTE	0.898
NYMT	0.897

10 Most Negative Correlations
OBT	-0.916
PRGS	-0.915
HTBI	-0.914
NWPX	-0.911
KTCC	-0.909
VC	-0.907
HUBG	-0.897
JBSS	-0.889
WSC	-0.889
PRN	-0.886

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arcutis Biotherapeutics Correlation - Currency/Commodity

-0.89
( strong negative )

-0.91
( very strong negative )

0.00
( neutral )

-0.89
( strong negative )

0.21
( neutral )

0.85
( strong )

Arcutis Biotherapeutics Financials

Annual	2023
Revenue:	$59.61M
Gross Profit:	$53.49M (89.74 %)
EPS:	$-3.78

Q4	2023
Revenue:	$13.53M
Gross Profit:	$11.08M (81.93 %)
EPS:	$-0.720

Q3	2023
Revenue:	$38.11M
Gross Profit:	$36.93M (96.90 %)
EPS:	$-0.730

Q2	2023
Revenue:	$5.19M
Gross Profit:	$4.41M (85.05 %)
EPS:	$-1.160

Financial Reports:

No articles found.

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.